Fundraising Fox
Phoenix Molecular Designs
Founded 2012 · 11 employees on LinkedIn · 3 known investors
Find your way into Phoenix Molecular Designs
Each arrow is one introduction. Sign up to fill in the first one.
Ask Shahid Nimjee to introduce you to Sandra Dunn
You →Shahid · together at Biotech CEO Sisterhood →Sandra
Ask Jamie Chen to introduce you to Martin S. Olivo
You →Jamie · together at Protara Therapeutics →Martin
Ask Sam Okafor to introduce you to Joe Ninosky
You →Sam · together at Revelation Biosciences →Joe
Sign up to find every way you can get introduced to Phoenix Molecular Designs
- Your email: who you already know at Phoenix Molecular Designs, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Phoenix Molecular Designs team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Phoenix Molecular Designs (PhoenixMD) is a biotechnology company developing targeted breast cancer therapeutics, including PMD-026, a first-in-class RSK2 inhibitor in Phase 2 clinical trials paired with a companion diagnostic. The company applies medicinal chemistry, computational modeling, and cancer biology to treat breast cancer and other cancers.
Also known as PhoenixMD
Founders & leadership
Phoenix Molecular Designs was founded in 2012 by Sandra Dunn.
Investors · 3
How we know: the VCSheet dataset · Not right? Tell us
How we know: funding news · prnewswire.com · Not right? Tell us
Funding
SEC filings, press & company announcements$2.7M disclosed across 1 of 2 rounds · 2018–2019
- Undisclosed amountSeedNov 2019Source ↗
- $2.7MraisedSep 2018 · 3 sources
Pallasite Ventures (lead)
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Company profile
researched Aug 2026Phoenix Molecular Designs (PhoenixMD) is a biotechnology company focused on the design of precise cancer therapeutics. Its work centers on developing novel drugs that target RSK, a kinase the company describes as a driver of cancerous tumor growth and metastasis that has historically been considered undruggable.
The company positions its programs around personalized and alternative cancer therapeutics intended to preserve patient quality of life. Its lead compound, PMD-026, is discussed in oncology trade coverage in the context of RSK-driven breast cancer, a patient group described as having had limited treatment options.
Latest developments
An OncLive feature covered the science behind PMD-026 and its potential in RSK-driven breast cancer, with commentary from Dr. Hung Khong of Banner MD Anderson Cancer Center on RSK inhibition in RSK-high, CDK4/6 inhibitor-resistant breast cancer.
▸Full profile — market position, technology, go-to-market
Market position
The company presents itself as working on a target, RSK, that has not previously been successfully drugged, addressing RSK-driven breast cancer where treatment options have been limited.
Technology
The company's technology is directed at pharmacological inhibition of RSK, a target it characterizes as previously undruggable, with the aim of blocking a driver of tumor growth and metastasis. PMD-026 is the compound associated with this approach.
Go-to-market
Patients with cancer, and specifically patients with RSK-driven breast cancer, together with the oncologists and cancer centers treating them.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
In the news
▸Research sources · 1
primary sources listed
- Phoenix Molecular Designsphoenixmd.ca · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Phoenix Molecular Designs do?
- Biotechnology company designing precise cancer therapeutics targeting RSK, a driver of tumor growth and metastasis.
- Who founded Phoenix Molecular Designs?
- Phoenix Molecular Designs was founded by Sandra Dunn in 2012.
- Who are Phoenix Molecular Designs's investors?
- Phoenix Molecular Designs's investors include Eshelman Ventures, LLC, Flucas Ventures, Pallasite Ventures.
- How much funding has Phoenix Molecular Designs raised?
- Phoenix Molecular Designs has disclosed $2.7M raised across 1 of its 2 known rounds.